| NCT#: & Link | NCT05503797 |
| NCT QR Code |  |
| Available as of: | October 2, 2024 |
| Contract: | Caris |
| Indication Category: | Brain/Spine |
| Study Sponsor: | Fore Biotherapeutics |
| Protocol #: | F8394-201: Subprotocol A & B |
| Title: | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations |
| Highlight Details: | A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations |
| Biomarkers: | BRAF Fusions/BRAF V600E |
| Indication: | Solid Tumors/CNS tumors |
| Phase: | 2 |
| Treatment Line: | |
| Study Drug/Test Compound: | FORE8394 |
| Notes | |
| Recruitment Status: | Just In Time |
| Participating Institution: | Salinas Valley Health |
| Salinas Valley Health Clinical Research Program: | Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, research@salinasvalleyhealth.com |
